Skip to content

Cardiac Assessment After Covid-19 Disease in Elite Altheltic Population

Evaluation of Cardiological Tests Before Returning to Sport in Athletes After COVID-19 Infection (CADE Study)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04653857
Acronym
CADE
Enrollment
250
Registered
2020-12-04
Start date
2020-04-01
Completion date
2021-01-01
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

High-level athlete, recent COVID 19 infection, symptomatic or not

Brief summary

COVID-19 infection coud induce cardiac injuries. Before returning to sport, cardiac evaluation is recommended by sports federations, based on the precautionary principle and the opinion of expert consensus. The aim of this study is to to determine the prevalence of abnormalities in cardiological examinations realized in athletes who have suffered from COVID-19 infection, symptomatic or not.

Detailed description

Cardiac injuries linked to COVID-19 infection are frequently described in symptomatic and hospitalized people and are associated with a poorer prognosis. The question of possible myocardial damage in people without or moderately symptomatic is less established. The presence of a myocarditis associated with COVID-19 infection is a key issue for the sports cardiologist since this cardiac inflammation may be associated with an increased risk of sudden death in the athlete. In absence of scientific data and on the basis of the precautionary principle, the ministry (Guide to health recommendations for sports resumption, Sports French Ministry, May 2020), sports federations and certain expert consensus have proposed in May 2020 after being released from lockdown, algorithms for carrying out systematic cardiac examinations before resuming intense sport (professional or high-level athletes). These algorithms typically provide a comprehensive cardiac assessment with resting ECG, resting echocardiography, and maximal exercice test. The performance of cardiac MRI, the most sensitive exam for detecting possible myocarditis, remains at the discretion of the cardiologist depending on the interpretation of the first examinations. Given a much larger screening for COVID-19 infection than in March, with the performance of virological PCR tests required weekly by certain sports federations, the prevalence of COVID-19 infection is important in the athletic population, mostly in a- or pauci-symptomatic athletes. In case of positivity, a cardiac evaluation is therefore often recommended. The aim of this study is to determine the prevalence of cardiac abnormality encountered during cardiac examinations performed in athletes before resuming intense sport, after infection with COVID-19. The target population is High-level athlete (professionals or high-level ministerial list), who had a recent COVID 19 infection, symptomatic or not To perform this study, the investigators will use existing data from patients' medical records (March 2019, March 2021). Anonymized data will be provided to the methodological team for analysis. The data will be kept for 2 years after publication. The data collected will be : * the sport practiced * Age and sex * Date of positive PCR * Classification of the symptom intensities related to COVID-19 infection: (asymptomatic, mild symptoms, moderate symptoms, cardiac symptoms) * 12-lead resting electrocardiogram (heart rate, interpretation by the cardiologist, anomaly or not) * Maxmal exercice test (maximum heart rate, maximum power or speed, oxygen saturation, presence of arrhythmia or not) * Resting echocardiography (LVEF, overall LV longitudinal strain, abnormal or not in segmental kinetics, presence or not of pericardial effusion) * MRI (if done): LVEF, presence of an abnormality or not, in particular late enhancement * Holter ECG if done (presence or not of arrhythmia) * Biology if done (increase or not in troponin or D-Dimers

Interventions

None listed

Sponsors

Clinique du Millenaire
CollaboratorOTHER
Centre Hospitalier Universitaire de Nīmes
CollaboratorOTHER
Centre hospitalier de Perpignan
CollaboratorOTHER
ligue nationale de Basket
CollaboratorUNKNOWN
Rennes University Hospital
CollaboratorOTHER
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
10 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* High-level athlete * recent COVID 19 infection, symptomatic or not * evidence of COVID 19 infection by PCR or serology

Exclusion criteria

\- subject opposition

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of cardiac abnormality1 to 3 weeks after COVID-19 infectionPrevalence of cardiac abnormality encountered during examinations performed in athletes before resuming intense sport, after infection with COVID-19

Secondary

MeasureTime frameDescription
Demographic variables1 to 3 weeks after COVID-19 infectionDemographic variables associated with detected cardiac abnormalities

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026